【原】文献阅读003：单细胞肿瘤浸润性髓系细胞的异质性(综述)

综述主要介绍了Mast、Dendritic、Monocyte、Macrophage、Neutrophils细胞，其中Neutrophils不是很详细，因此只总结了前4中细胞的亚群marker和特征。以思维导图形式总结在幕布，方便以后增删改查。

幕布文档链接: https://www./doc/7V2nk7N6B_1 密码: 9adx

Mast

marker: TPSAB1, CPA3, KIT, MS4A2

1. high proportion in cancer than normal tissue;
2. down-regulate the expression of TNF;
3. 在不同癌症中其量与预后有正反关系;
4. 高表达VEGFA促进血管新生
5. 表达IL10,TGFB, 招募Treg促进免疫抑制
6. 高表达PD-L1
7. 释放CCL3、CCL5招募T和NK

Dendritic

Conventional DC (cDC)

cDC1

marker: XCR1, CLEC9A, BATF3, IRF8

1. mainly antitumor

cDC2

marker: CLEC10A, FCER1A, CD1C, CD1E

1. 促进Th2、抑制Th17、与CD4+ T互作促进肿瘤
2. activates antitumor CD4+ conventional T cells (Tconvs) in the absence of Treg

Plasmacytoid DC (pDC)

marker: MZB1, LILRA4, IRF7, IL3RA

1. immunosuppressive；
2. anti-tumor: release IFNα/β & TNFα

LAMP3+ DC (mregDC)

marker: LAMP3, BIRC3, CCR7, FSCN1

1. high expression of LAMP3, immune regulators [CD274 & FAS], maturation genes (CD40 & CD80) and migratory genes (CCR7 & FSCN1)

2.enriched in intratumor & invasive margin tumor tissues;

1. originate: cDC1 and cDC2,;
2. high expression of CCL17, CCL19 & CCL22;
3. suppress CD8+ T cells self-renew and function through PD-L1/PD-1 pathway;
4. interact with CD8+ T cells from cDC1 ;
5. interact with Tregs from cDC2;recuit Treg;

C3

marker: CD88−CD1c+CD163+

1. pro-inflammatory: trigger the expansion of tissue-resident memory CD8+ T cells and enhance MHC expression
2. intermediated functional subtype between cDC2 and monocyte, produces TNFα as monocyte & IL23, IL12p70 as cDC2

Monocyte

Classical monocyte

marker: FCN1, CD14, S100A8, VCAN

Nonclassical monocyte

marker: FCN1, FCGR3A, LILRB2, LST1

Intermediate monocyte

marker: FCN1, CD14, FCGR3A

Macrophage

classically activated macrophages (M1)

1. 由Toll样受体配体[如脂多糖和干扰素-γ]诱导)
2. 表达促炎细胞因子和诱导型一氧化氮合酶
3. 增强抗肿瘤 Th1 反应并拮抗调节性免疫细胞的抑制活性

alternatively activated macrophages (M2)

1. 由IL-4或IL-13诱导
2. 表达精氨酸酶1、CD206、CD163、IL-4R、TGF-β1和血小板衍生生长因子(PDGF)
3. 促进血管生成、肿瘤生长和转移

Monocyte-like macrophages

marker: FCN1, CD163, CD68

FOLR2+ TRM

marker: FOLR2, MRC1

1. enrich: tumor stroma
2. prime effector CD8+ T cells
3. beneficial to survival

TREM+ recruited macrophages

1. enrichment and activation of T cells and nature killer (NK) cells, which furtherly enhanced ICB therapy

MDSCs-like macrophages

marker: MARCO  & TREM1

1. Myeloid-derived suppressor cells

TAM-like macrophage

marker: CD169, CX3CR1, TREM2

1. immature macrophage;
2. Enriched in TME with T cells infiltrated or excluded

LYVE1+ TRM

marker: LYVE1, C1QC, PLTP, SEPP1

1. locate: adjacent to blood vessels

NLRP3+ TRM

marker: NLRP3, IL1B, CXCL2, EREG

1. promote the inflammatory response

Alveolar TRM

marker: PPARG, MARCO, MRC1, MSR1

1. canonical TRM

ISG15+ TAM

marker: ISG15, CXCL10, IFITM3, GBP1

C1QC+ TAM

marker: C10A, C1QB, C1QG, APOE

1. phagocytosis and antigen presentation
2. originate: FCN1+ monocytes
3. locate: adjacent zones

SPP1+ TAM

marker: SPP1, VEGFA, GPNMB, FN1

1. angiogenesis;
2. worse prognosis;
3. associate with ICB drug resistance
4. interact with tumor-specific FAP+ fibroblasts to promote tumor progression
5. SPP1+ macrophages and TREM2+ macrophages might largely be overlapped with each other